Tuberculosis after a borderline QuantiFERON result during screening before infliximab

European Respiratory Journal

Volumn 52, Issue 2, 2018, Pages

  Uzorka, Jonathan W ^a   Delfos, Nathalie M ^b   Witte, Anne M C ^b   Scheper, Henk ^a   Van Soolingen, Dick ^c   Arend, Sandra M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ALRIJNE HOSPITAL   (Netherlands)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; ETHAMBUTOL; INFLIXIMAB; ISONIAZID; MESALAZINE; PREDNISONE; PYRAZINAMIDE; RIFAMPICIN;

ADULT; CASE REPORT; CLINICAL ARTICLE; DISEASE COURSE; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; MILIARY TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NIGHT SWEAT; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; SCREENING; TUBERCULIN TEST; ULCERATIVE COLITIS; INTERFERON GAMMA RELEASE ASSAY; TUBERCULOSIS;

HUMANS; INFLIXIMAB; INTERFERON-GAMMA RELEASE TESTS; TUBERCULOSIS;

EID: 85051462249     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00913-2018     Document Type: Letter

References (11)

1. Migliori GB, Sotgiu G, Rosales-Klintz S, et al. ERS/ECDC Statement: European Union standards for tuberculosis care, 2017 update. Eur Respir J 2018; 51: 1702678.
2. Bumbacea D, Arend SM, Eyuboglu F, et al. The risk of tuberculosis in transplant candidates and recipients: A TBNET consensus statement. Eur Respir J 2012; 40: 990-1013.
3. Uzorka JW, Kroft LJM, Bakker JA, et al. Proof of concept that most borderline QuantiFERON results are true antigen-specific responses. Eur Respir J 2017; 50: 1701630.
4. Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: A TBNET consensus statement. Eur Respir J 2010; 36: 1185-1206.
5. Cantini F, Nannini C, Niccoli L, et al. Risk of tuberculosis reactivation in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis receiving non-anti-TNF-targeted biologics. Mediators Inflamm 2017; 2017: 8909834.
6. Ai JW, Zhang S, Ruan QL, et al. The risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor-alpha antagonist: A metaanalysis of both randomized controlled trials and registry/cohort studies. J Rheumatol 2015; 42: 2229-2237.
7. Farhat M, Greenaway C, Pai M, et al. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis 2006; 10: 1192-1204.
8. Leyten EM, Arend SM, Prins C, et al. Discrepancy between Mycobacterium tuberculosis-specific gamma interferon release assays using short and prolonged in vitro incubation. Clin Vaccine Immunol 2007; 14: 880-885.
9. Nemes E, Rozot V, Geldenhuys H, et al. Optimization and interpretation of serial QuantiFERON testing to measure acquisition of Mycobacterium tuberculosis infection. Am J Respir Crit Care Med 2017; 196: 638-648.
10. Uzorka JW, Bossink AWJ, Franken WPJ. Borderline QuantiFERON results and the distinction between specific responses and test variability. Tuberculosis 2018; 111: 102-108.
11. Jonsson J, Westman A, Bruchfeld J, et al. A borderline range for QuantiFERON Gold In-Tube results. PLoS One 2017; 12: E0187313.